Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AASLD Briefs: Merck HCV Combo’s Four- and Six-Week Data Disappoint, Upside Seen For Gilead

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck’s proprietary two-drug combo, when used with Sovaldi, did not produce strong cure rates in short-term therapy, but an eight-week regimen in treatment-naïve cirrhotic patients may offer an advantage over Harvoni. Also, researchers estimate the total cost to treat HCV and recommend need-based prioritization of therapy.

Advertisement
Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS076617

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel